Mind the gap in kidney care: Translating what we know into what we do

被引:0
|
作者
Luyckx, Valerie A. [1 ,2 ,3 ]
Tuttle, Katherine R. [4 ,5 ]
Abdellatif, Dina [6 ]
Correa-Rotter, Ricardo [7 ]
Fung, Winston W. S. [8 ]
Haris, Agnes [9 ]
Hsiao, Li-Li [2 ]
Khalife, Makram [10 ]
Kumaraswami, Latha A. [11 ]
Loud, Fiona [10 ]
Raghavan, Vasundhara [10 ]
Roumeliotis, Stefanos [12 ]
Sierra, Marianella [10 ]
Ulasi, Ifeoma [13 ]
Wang, Bill [10 ]
Lui, Siu-Fai [14 ]
Liakopoulos, Vassilios [12 ]
Balducci, Alessandro [15 ]
机构
[1] Univ Zurich, Epidemiol Biostat & Prevent Inst, Dept Publ & Global Hlth, Hirschengraben 84, CH-8001 Zurich, Switzerland
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Renal Div, Boston, MA 02115 USA
[3] Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa
[4] Providence Inland Northwest Hlth, Providence Med Res Ctr, 105 W 8th Ave,Suite 250 E, Spokane, WA 99204 USA
[5] Univ Washington, Dept Med, Div Nephrol, Seattle, WA USA
[6] Cairo Univ, Dept Nephrol, Pediat Hosp, Cairo, Egypt
[7] Natl Med Sci & Nutr Inst Salvador Zubiran, Dept Nephrol & Mineral Metab, Mexico City, DF, Mexico
[8] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Ninth Floor,Lui Che Woo Clin Sci Bldg,32 Ngan Shi, Hong Kong, Peoples R China
[9] Peterfy Hosp, Neurol Dept, Budapest, Hungary
[10] ISN, ISN Patient Liaison Advisory Grp, Brussels, Belgium
[11] Tamilnad Kidney Res Tanker Fdn, Chennai, Tamil Nadu, India
[12] Aristotle Univ Thessaloniki, AHEPA Hosp, Sch Med, Dept Nephrol 2, Thessaloniki, Greece
[13] Univ Nigeria, Coll Med, Dept Med, Ituku Ozalla, Enugu State, Nigeria
[14] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Div Hlth Syst Policy & Management, Shatin, Hong Kong, Peoples R China
[15] Italian Kidney Fdn, Rome, Italy
关键词
chronic kidney disease; equity; kidney care; public health; World Kidney Day; MIDDLE-INCOME; DISEASE; CKD; MANAGEMENT; MEDICINES; BARRIERS; OUTCOMES; BURDEN; RISK;
D O I
10.1111/jorc.12495
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
引用
收藏
页码:79 / 91
页数:13
相关论文
共 50 条
  • [41] Interstitial lung abnormalities: What do we know and how do we manage?
    Liu, Qi
    Zhang, Hai
    Han, Baohui
    Jiang, Handong
    Chung, Kian Fan
    Li, Feng
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (12) : 1551 - 1561
  • [42] GLIM in chronic kidney disease: What do we need to know?
    Silva, Maryanne Zilli Canedo
    Cederholm, Tommy
    Gonzalez, Maria Cristina
    Lindholm, Bengt
    Avesani, Carla Maria
    CLINICAL NUTRITION, 2023, 42 (06) : 937 - 943
  • [43] What do we know about biomarkers in diabetic kidney disease?
    Kwiendacz, Hanna
    Nabrdalik, Katarzyna
    Stompor, Tomasz
    Gumprecht, Janusz
    ENDOKRYNOLOGIA POLSKA, 2020, 71 (06) : 545 - 550
  • [44] IgA Nephropathy in India: What We Do Know
    Chacko, Bobby
    RENAL FAILURE, 2011, 33 (01) : 102 - 107
  • [45] The Interplay of Autophagy and Oxidative Stress in the Kidney: What Do We Know?
    Guo, Haihua
    Bechtel-Walz, Wibke
    NEPHRON, 2023, 147 (10) : 627 - 641
  • [46] Chronic Kidney Disease of Unknown Etiology in India: What Do We Know and Where We Need to Go
    John, Oommen
    Gummudi, Balaji
    Jha, Anubhuti
    Gopalakrishnan, Natarajan
    Kalra, Om P.
    Kaur, Prabhdeep
    Kher, Vijay
    Kumar, Vivek
    Machiraju, Ravi Shankar
    Osborne, Nicolas
    Palo, Subrata Kumar
    Parameswaran, Sreejith
    Pati, Sanghamitra
    Prasad, Narayan
    Rathore, Vinay
    Rajapurkar, Mohan M.
    Sahay, Manisha
    Tatapudi, Ravi Raju
    Thakur, Jarnail S.
    Venugopal, Vidhya
    Jha, Vivekanand
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (11): : 2743 - 2751
  • [47] Productive effects of public works programs: What do we know? What should we know?
    Gehrke, Esther
    Hartwig, Renate
    WORLD DEVELOPMENT, 2018, 107 : 111 - 124
  • [48] An epistemology for assessment and development: how do we know what we know?
    Rupp, Deborah E.
    Thornton III, George C.
    Bisbey, Tiffany M.
    Hoover, Anna N.
    Salas, Eduardo
    Murphy, Kevin R.
    INDUSTRIAL AND ORGANIZATIONAL PSYCHOLOGY, 2024, 17 (02) : 252 - 268
  • [49] What We Know and What We Don't Know About Preventing Stroke
    Burch, Druin
    PLOS MEDICINE, 2014, 11 (04)
  • [50] Dysfunctional breathing: what do we know?
    Vidotto, Lais Silva
    Fernandes de Carvalho, Celso Ricardo
    Harvey, Alex
    Jones, Mandy
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2019, 45 (01)